Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors
Rezaul M. Karim, Melissa J. Bikowitz, A. Chan, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 21, pp. 15772-15786
Open Access | Times Cited: 18

Showing 18 citing articles:

Binding Mechanism of Inhibitors to BRD4 and BRD9 Decoded by Multiple Independent Molecular Dynamics Simulations and Deep Learning
Jian Wang, Wanchun Yang, Lu Zhao, et al.
Molecules (2024) Vol. 29, Iss. 8, pp. 1857-1857
Open Access | Times Cited: 13
Differential scanning fluorimetry followed by microscale thermophoresis and/or isothermal titration calorimetry as an efficient tool for ligand screening
Maria Winiewska‐Szajewska, Jarosław Poznański
Biophysical Reviews (2025) Vol. 17, Iss. 1, pp. 199-223
Open Access | Times Cited: 1
Discovery of Dual TAF1-ATR Inhibitors and Ligand-Induced Structural Changes of the TAF1 Tandem Bromodomain
Rezaul M. Karim, Leixiang Yang, Lihong Chen, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 5, pp. 4182-4200
Closed Access | Times Cited: 20
Binding Selectivity of Inhibitors to BRD2 Uncovered by Molecular Docking and Molecular Dynamics Simulations
Qian Bai, Ruige Wang, Shili Qin, et al.
Advanced Theory and Simulations (2025)
Closed Access
Macrocyclic Dihydropyridine Analogs as pan-BET BD2-Preferred Inhibitors
Jiewei Jiang, T. Jake Liang, Jonathan Solberg, et al.
European Journal of Medicinal Chemistry (2025), pp. 117504-117504
Closed Access
Selective mechanism of inhibitors to two bromodomains of BRD4 revealed by multiple replica molecular dynamics simulations and free energy analyses
Meng Li, Xinguo Liu, Shaolong Zhang, et al.
Chinese Journal of Chemical Physics (2023) Vol. 36, Iss. 6, pp. 725-739
Open Access | Times Cited: 7
CK2 Inhibitors Targeting Inside and Outside the Catalytic Box
Sophie Day-Riley, R. WEST, P. Brear, et al.
Kinases and Phosphatases (2024) Vol. 2, Iss. 2, pp. 110-135
Open Access | Times Cited: 2
Bivalent BET Bromodomain Inhibitors Confer Increased Potency and Selectivity for BRDT via Protein Conformational Plasticity
Xianghong Guan, Narsihmulu Cheryala, Rezaul M. Karim, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 15, pp. 10441-10458
Closed Access | Times Cited: 11
Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer
Chunlong Zhao, Yu Zhang, Jin’ge Zhang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 20, pp. 14150-14174
Closed Access | Times Cited: 6
Recent Advances in Dual BRD4‐Kinase Inhibitors Based on Polypharmacology
Li Chen, Zhao‐Peng Liu, Xun Li
ChemMedChem (2022) Vol. 17, Iss. 6
Closed Access | Times Cited: 9
Identifying Protein–Ligand Interactions via a Novel Distance Self-Feedback Biomolecular Interaction Network
Yurong Zou, Ruihan Wang, Meng Du, et al.
The Journal of Physical Chemistry B (2023) Vol. 127, Iss. 4, pp. 899-911
Closed Access | Times Cited: 4
Structure-Based Rational Design and Evaluation of BET-Aurora Kinase Dual-Inhibitors for Treatment of Cancers
Kaikai Lyu, Ying Ren, Jie Mou, et al.
Journal of Medicinal Chemistry (2024) Vol. 68, Iss. 2, pp. 1344-1364
Closed Access | Times Cited: 1
Novel Aminopyrimidine-2,4-diones, 2-Thiopyrimidine-4-ones, and 6-Arylpteridines as Dual-Target Inhibitors of BRD4/PLK1: Design, Synthesis, Cytotoxicity, and Computational Studies
Samar El‐Kalyoubi, Samiha A. El‐Sebaey, Sherin M. Elfeky, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 9, pp. 1303-1303
Open Access | Times Cited: 3
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma
Filippo Spriano, Giulio Sartori, Chiara Tarantelli, et al.
eJHaem (2022) Vol. 3, Iss. 3, pp. 764-774
Open Access | Times Cited: 3
Non-Kinase Off-Target Inhibitory Activities of Clinically-Relevant Kinase Inhibitors
Nickolas R. Brauer, Allison L. Kempen, Delmis E. Hernandez, et al.
European Journal of Medicinal Chemistry (2024) Vol. 275, pp. 116540-116540
Closed Access
Identification of Novel Bromodomain-Containing Protein 4 (BRD4) Binders through 3D Pharmacophore-Based Repositioning Screening Campaign
Ester Colarusso, Erica Gazzillo, Eleonora Boccia, et al.
Molecules (2024) Vol. 29, Iss. 17, pp. 4025-4025
Open Access
1,4‐Dihydropyridinebutyrolactone‐derived ring‐opened ester and amide analogs targeting BET bromodomains
Jiewei Jiang, Pei‐Liang Zhao, Logan H. Sigua, et al.
Archiv der Pharmazie (2022) Vol. 355, Iss. 11
Open Access | Times Cited: 2
Photoaffinity labelling displacement assay using multiple recombinant protein domains
David J. Fallon, Alex Phillipou, Christopher J. Schofield, et al.
Biochemical Journal (2023) Vol. 480, Iss. 15, pp. 1183-1197
Open Access
Page 1

Scroll to top